|
|
The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second WavePublished by: BioSeeker Group AB Published: Nov. 22, 2005 Table of ContentsThe Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave 1 Executive Summary 2 Cancer Highlights 3 Methodology 4 Table of Contents 4.1 List of Boxes 4.2 List of Tables 5 Key Developmental Strategies 6 Treating Colorectal Cancer 6.1 Avastin 6.1.1 Avastin -Major Developmental Milestones 6.1.2 Sales Predictions on Avastin 6.1.3 Avastin Related Studies 6.2 Erbitux 6.2.1 Erbitux -Major Developmental Milestones 6.2.2 Sales Predictions on Erbitux 6.2.3 Erbitux Related Studies 7 Treating Lymphomas 7.1 Rituxan 7.1.1 Sales Predictions on Rituxan 7.1.2 Rituxan -Major Developmental Milestones 7.1.3 Rituxan Related Studies 7.2 Bexxar 7.2.1 Sales Predictions on Bexxar 7.2.2 Bexxar -Major Developmental Milestones 7.2.3 Bexxar Related Studies 7.3 Zevalin 7.3.1 Sales Predictions on Zevalin 7.3.2 Zevalin -Major Developmental Milestones 7.3.3 Zevalin Related Studies 8 Treating Leukemias 8.1 ALL 8.2 CLL 8.3 AML 8.4 CML 8.5 Campath 8.5.1 Campath -Major Developmental Milestones 8.5.2 Campath Related Studies 8.6 Mylotarg 8.6.1 Mylotarg Related Studies 9 Treating Lung cancer 9.1 Cotara 10 Antibody Deals on the Rise 10.1 Antibody Deals in Phase III 10.1.1 Deal Situation: MDX 010 10.1.2 Deal Situation: WX G250 10.1.3 Deal Situation: Zanolimumab 10.2 Antibody Deals in Phase II 10.2.1 Deal Situation: Mapatumumab 10.2.2 Deal Situation: GCR 3888 10.2.3 Deal Situation: MDX 070 10.2.4 Deal Situation: CDP 860 10.2.5 Deal Situation: Tru-Scint OV 10.2.6 Deal Situation: SC 1 10.2.7 Deal Situation: PRO 70769 10.2.8 Deal Situation: XR 303 10.2.9 Deal Situation: HumaRAD-HN 11 New Approaches in Antibody Delivery and Design - The Next Generation 11.1 How to Make Them Smaller and Different? 11.2 Biomaterials in Sustained Delivery Applications 11.2.1 Implants 11.3 Gene delivery - the Future? 11.3.1 Delivery Vehicles for DNA 11.3.2 Gene Delivery in Commercialization 12 Current Analysis of Mabs in Clinical Development 12.1.1 Prostate Cancer Therapeutics 12.1.2 Breast Cancer Therapeutics 12.1.3 Colorectal Cancer Therapeutics 12.1.4 Melanoma Therapeutics 12.1.5 Hematological Cancers Therapeutics 12.2 Mabs in Late Stage of Development 12.2.1 MAbs in Phase III Clinical Development 12.2.2 Mabs in Phase II Clinical Development 13 Appendix I: Cancer Therapeutic Antibodies in Clinical Development 14 Appendix II: Discontinued Projects - A Five Year Recapitulation 15 Appendix III: Selected Company Profiles 16 Disclaimer 17 Drug Index 18 Company Index 4.1 List of Boxes Box 1: The Principal Terms of Deal between AstraZeneca and Cambridge Antibody Technology Box 2: Marrion’s Drug Delivery Technology Box 3: Quick Facts - CeaVac Box 4: Quick Facts - Elsilimomab Box 5: Quick Facts - IGN 101 Box 6: Quick Facts - IMC-BEC2 Box 7: Quick Facts - MDX 010 Box 8: Quick Facts - ONYVAX 105 Box 9: Quick Facts - Ovarex Box 10: Quick Facts - Panitumumab Box 11: Quick Facts - RENCARNEX Box 12: Quick Facts - Nimotuzumab Box 13: Quick Facts - RENCARNEX Box 14: Quick Facts - Lintuzumab Box 15: Quick Facts - Zanolimumab Box 16: Quick Facts - ABT-510 Box 17: Quick Facts - BB 10901 Box 18: Quick Facts - CP-675206 Box 19: Quick Facts - CNTO-328 Box 20: Quick Facts - Ecromeximab Box 21: Quick Facts - EMD-273063 Box 22: Quick Facts - WX-G250RIT Box 23: Quick Facts - HGS-ETR1 Box 24: Quick Facts - HuMax-CD20 Box 25: Quick Facts - HuMax-EGFr Box 26: Quick Facts - Galizimab Box 27: Quick Facts - PROXINIUM Box 28: Quick Facts - RAV12 Box 29: Quick Facts -SGN-15 Box 30: Quick Facts -SGN-30 Box 31: Quick Facts - VEGF-Trap Box 32: Quick Facts - MEDI 522 Box 33: Quick Facts - Volociximab Box 34: Quick Facts - Zanolimumab 4.2 List of Tables Table 1: Summary of Strategies Enhancing Antibody Function Table 2: Potential Advantages in Local, Controlled-Release for Therapeutic Antibodies Table 3: Drug Delivery Companies with Cancer Focus Table 4: FDA Approved Polymer-based Drug Delivery Systems for Cancer Table 5: Antibody Therapeutics in Prostate Cancer Table 6: Antibody Therapeutics in Breast Cancer Table 7: Antibody Therapeutics in Colorectal Cancer Table 8: Antibody Therapeutics in Melanoma Table 9: Antibody Therapeutics in Hematological Cancer Table 10: MDX-010’s Collaborative History and Landscape AbstractExecutive SummaryFull Title: The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave Introduction The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Scope of this report
The commercial and therapeutic success of antibodies will force the industry to look into the next generation of therapeutic antibodies, preparing themselves for the second wave in the lucrative field of therapeutic antibodies. The first-generation formulations of therapeutic antibodies will be facing heavy competition from biogeneric companies as their profitable antibody drugs comes off patent in the future. Among the different strategies (e.g., antibody engineering, changes in primary structure, fusions, chemical modifications glycosylation, pegylation, polymer conjugates), the approach of miniaturizing and delivering antibody drugs is the most promising because it permits better release of active drugs. Key reasons to read this report
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||